Mary Van Beusekom | News Writer | CIDRAP News
May 25, 2020
Despite US COVID-19 deaths approaching 100,000, crowds still gathered in many parts of the United States over the Memorial Day weekend, as the World Health Organization (WHO) today announced a pause on global hydroxychloroquine studies that it is leading. ...
Hydroxychloroquine trial paused over safety concerns
At a media briefing today, WHO Director-General Tedros Adhanom Ghebreyesus, PhD, said that a WHO drug trial executive group has recommended a temporary pause to allow the Data Safety Monitoring Board of the Solidarity trial to review the malaria drug hydroxychloroquine for treating the novel coronavirus.
The move follows the publication of a recent observational study in The Lancet that found that hydroxychloroquine and chloroquine were associated with a higher risk of death and serious heart rhythm complications, The executive group met on May 23 to review the data. ...
May 25, 2020
Despite US COVID-19 deaths approaching 100,000, crowds still gathered in many parts of the United States over the Memorial Day weekend, as the World Health Organization (WHO) today announced a pause on global hydroxychloroquine studies that it is leading. ...
Hydroxychloroquine trial paused over safety concerns
At a media briefing today, WHO Director-General Tedros Adhanom Ghebreyesus, PhD, said that a WHO drug trial executive group has recommended a temporary pause to allow the Data Safety Monitoring Board of the Solidarity trial to review the malaria drug hydroxychloroquine for treating the novel coronavirus.
The move follows the publication of a recent observational study in The Lancet that found that hydroxychloroquine and chloroquine were associated with a higher risk of death and serious heart rhythm complications, The executive group met on May 23 to review the data. ...
Comment